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Abstract: STAT1 and STAT3 are nuclear transcription factors that regulate genes involved in cell cycle,
cell survival and immune response. The cross-talk between these signaling pathways determines
how cells integrate the environmental signals received ultimately translating them in transcriptional
regulation of specific sets of genes. Despite being activated downstream of common cytokine and
growth factors, STAT1 and STAT3 play essentially antagonistic roles and the disruption of their
balance directs cells from survival to apoptotic cell death or from inflammatory to anti-inflammatory
responses. Different mechanisms are proposed to explain this yin-yang relationship. Considering
the redox aspect of STATs proteins, this review attempts to summarize the current knowledge of
redox regulation of STAT1 and STAT3 signaling focusing the attention on the post-translational
modifications that affect their activity.
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1. Introduction
Signal Transducer and Activator of Transcription 1 and 3 (STAT1 and STAT3) are members of a
family of seven transcriptional factors (STAT1, 2, 3, 4, 5a, 5b and 6) essential for the cellular response to
cytokines and growth factors. They regulate several biological events such as embryonic development,
organogenesis, innate and adaptive immunity, cells growth and differentiation, and programmed cell
death. In resting cells, STATs proteins are latent in cytoplasm and they translocate to the nucleus
after specific stimuli. The classical activation pathway involves the binding of cytokines or growth
factors to a specific receptor on cell surface and successive phosphorylation on conserved tyrosine and
serine residues by Janus tyrosine kinases (JAKs) and Mitogen-Activated Protein Kinases (MAPKs),
respectively. This event allows the dimerization of phosphorylated STATs and their translocation into
the nucleus where they modulate the expression of target genes.
The cross-talk between signaling pathways determines how cells integrate the environmental
signals received, ultimately translating them in transcriptional regulation of specific sets of genes.
STATs transcription factors, being able to detect a variety of environmental signals and to transduce
them to the nucleus directly affecting gene regulation, are ideally suited to play a central role in
orchestrating the outcome of this cross-talk. Despite being activated downstream of common cytokine
and growth factor receptors, STAT1 and STAT3 pathway is reciprocally regulated and perturbation in
their balanced expression or phosphorylation levels may redirect cytokine/growth factor signals from
proliferative to apoptotic, or from inflammatory to anti-inflammatory.
This review attempts to summarize the current knowledge of redox regulation of STAT1 and
STAT3 signaling focusing the attention on the post-translational modifications that affect their activity.
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2. Signal Transducer and Activator of Transcription 1 and 3
2.1. STAT1 and STAT3 Structure
STAT1 and STAT3 proteins are composed of 750 and 770 amino acids, respectively. The 3D-structure
of both proteins has been resolved and two crystals for each one are deposited on the Protein Data
Bank: the unphosphorylated STAT1 (1YVL) and the Tyr701-phosphorylated STAT1-DNA complex
(1BF5) and the unphosphorylated STAT3 core fragment (3CWG) and the phosphorylated STAT3-DNA
complex (1BG1).
The STATs proteins have the same structural and functional domain organization constituted by
six functional domains: an N-terminal domain (NTD), a coiled-coil domain (CCD), a DNA-binding
domain (DBD), a α-helical linker domain (LD) a Src homology 2 domain (SH2D) and a C-terminal
transcriptional activation domain (TAD) (Figure 1).
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there is a tail segment that contains the Tyrosine and Serine phosphorylation sites.
They are unique among transcription factors in contai ing a phosphotyr sine binding SH2D that
is the most conserved among STAT family due to its key role in receptor recruitm nt, phosphorylation
and dimeriz ti . The differences in SH2D define the selective receptor b nding on each STATs.
The SH2D consists in an antiparallel β-shee with two α- lixes alongside forming a pocket containing
a crucial argini e residue (Arg602 in STAT1 and r 9 T3) that mediates the interaction with th
p osphate gr up [1]. T ese structural feat res make th SH2D able to recognize the phospho-tyrosine
residues on specific protein regions d termining the association with the activat d JAKs and the
reciprocal SH2-phosphotyrosine interactions of monomeric STATs to form homo- or heterodime s.
This conformati n is now referred to as a “parallel” STATs dimer. It is important to note that the
presence of yrosine phosphorylation stabilizes this dimer conformation while t e absence of phosphate
group requires a new rearrangement of th dimer [2,3]. Indeed, the study of unphosphorylate STAT1
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monomer forming a different dimer structure called “anti-parallel” with the SH2 domains of each
monomer at opp site extremities of the dimer (Figure 2) [4,5]. Moreover, the analysis of the crystal
structure of t e unpho phorylated STAT3 (PDB:3CWG) shows simil rity to the antiparallel boat-like
structu e of STAT1 [6]. Other than SH2D interaction, we have recently detected two cha n disulfides
between cys in 367 and cysteine 542 and betw en cysteine 418 and cysteine 426 (Cys367-Cys542 and
C 418-Cys426) responsible for STAT3 dimer stabilization [7].
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Phosphorylated STAT1 and STAT3 dimerize in parallel form by reciprocal interactions between
phosphotyrosine residues and SH2D domains. Non-phosphorylated STAT1 and STAT3 dimers have an
anti-parallel orientation of the bodies with SH2D domains o the opposite end of the dimers and the
NTD domains lodged between mo omer.
Another highly conserved motif is the NTD, nvolved in th active dimer formation, in the
interaction with transcription co- ctivators, in the regulation of nuclear translocation and in cooperative
binding to DNA. The CCD, formed by a f ur-helix bundle, is crit cal for recruitment of TAT1/3 t the
receptor and subsequent phosphorylatio as well as dimerization, and tains residues essential for
nuclear translocation and interact on with reg l t ry proteins.
Residues 300 to 500 comprise the DBD, a region of beta-sheet structures that binds a pecific
DNA seq nce, called Gamma- terferon Ac iva ed Site (GAS). Although con act with DNA is limited,
it occurs in both major and minor groove. The LD, or ginally described as an SH3 homology region,
consists of a highly elical fold and constitu es one f the most con erv d regions in the STAT
molecules [8]. It has been described that mutation in LD affects the DNA binding and switch off
signal ng afte INF-γ stimulation [9]. The TAD, the least conserved domain a o g the STATs, can be
absent due to alternative splicing, contributes to functional specifici y and transcriptional activation of
target genes [2,10–14]. It is involved in transcriptional activation and promotes the activation of STAT1
and 3 through the phosphorylation of conserved Tyr residue (Tyr701 in STAT1 and Tyr705 in
STAT3) that controls dimerization by intermolecular interaction with the SH2 domain of the dimer
partner. In addition, TAD contains a second conserved phospho-amino acid residue at the C-terminus,
a phospho-Ser (Ser727), that is essential for maximal transcriptional activation of STAT.
2.2. STAT1 and STAT3 Signaling Cascade
STATs proteins are latent in the cytoplasm of resting cells, either as monomers or unphosphorylated
dimers until they are activated by growth factors and cytokines that bind to a specific cell receptor.
STATs 1 and 3 signaling can be induced by either distinct or by the same set of cytokines and growth
factors (Table 1).
Despite being activated downstream of common cytokine and growth factor receptors, STAT1
and 3 activation is often cell type and ligand specific and, in a lot of conditions, play opposing roles in
regulating cancer cell growth, proliferation, cell survival, apoptosis and immune response. Each STAT
mediates its biological effects by trans-activating a unique profile of target genes dependently on the
interactions with STAT-associated regulatory factors [15–17].
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Table 1. Cytokines, growth factors and related JAKs involved in the activation of STAT1 and
STAT3 signaling.
Cytokines JAKs STATs
IFN-g JAK1, JAK2 STAT1
NP JAK1, (JAK2) STAT3
CT-1 JAK1, (JAK2) STAT3
G-CSF JAK1, (JAK2) STAT3
Leptin JAK2 STAT3
GH JAK2 STAT3
IFN-a/b JAK1, TYK2 STAT1/STAT3
IL-6 JAK1, (JAK2) STAT1/STAT3
IL-9 JAK1, JAK3 STAT1/STAT3
IL-10 JAK1, TYK2 STAT1/STAT3
IL-11 JAK1 STAT1/STAT3
IL-12 TYK2, JAK2 STAT1/STAT3
IL-19 JAK1, JAK2 STAT1/STAT3
IL-20 JAK1, JAK2 STAT1/STAT3
IL-21 JAK1, JAK3 STAT1/STAT3
IL-22 JAK1, TYK2 STAT1/STAT3
LIF JAK1, (JAK2) STAT1/STAT3
CNTF JAK1, (JAK2) STAT1/STAT3
OSM JAK1, (JAK2) STAT1/STAT3
The classical pathway of signal transduction mediated by STATs factors is activated through
the binding of the ligands to their cognate cell-surface receptors. This allows the rapid
trans-phosphorylation and activation of the JAKs kinases (JAK1, JAK2, JAK3 and TYK2) constitutively
associated with the cytoplasmic membrane-proximal regions of various receptors. The receptor
phospho-tyrosine residues manage the SH2-dependent recruitment of specific STATs, which in turn
become JAKs substrates. STATs are phosphorylated on conserved tyrosine residue near the C-terminus
(Tyr701 in STAT1 and Tyr705 in STAT3) and, after release from the receptor, homo- or hetero-dimerize
and enter the nucleus by a mechanism that is dependent on importin-Ran-mediated active transport
(Figure 3) [18–20].
Although STATs activation by JAKs is the best characterized pathway, STAT1 and STAT3 can also
be activated by receptors with intrinsic Tyrosine Kinase (RTK) activity such as EGFR and PDGFR,
and by non-receptor tyrosine kinases (NRTKs) other than JAKs, such as Src kinase and ABL [21].
Once in the nucleus, dimerized STAT1 and STAT3 bind specific regulatory sequences, small DNA
palindromic consensus sequence (TTCN2–4GAA) that marks a GAS element and activate or repress
transcription of target genes.
It has been reported that the maximal activation of STAT1 and 3 is achieved when also Ser727 is
phosphorylated. On the basis of the cellular setting, stimulus, and STAT member, several serine kinases,
including ERK1/2, p38 and pKC-d, are involved. Yet, adverse findings ascribe to Ser phosphorylation a
negative regulation on DNA binding [22].
This apparently linear order of events is indeed made complex by a lot of signals integration
from multiple cytokine receptors, mutations, selective dimerization, negative pathway regulation,
and post-translational modification of pathway members.
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Figure 3. STAT1 and STAT3 signaling pathway. Key steps of STAT1 and STAT3 signaling in
response to cytokines. Binding of the ligands to the receptors induces receptor dimerization and
activation of receptor associated JAK kinase, which in turn phosphorylates STAT1 and STAT3 proteins.
Active STAT1/3 form dimer and translocate to the nucleus to control gene expression. The scheme
focuses on the opposing roles of STAT1 and STAT3 transduction cascade.
2.3. Negative Regulation of STAT1 and STAT3 Signaling
A number of studies has identified negative regulatory mechanisms that exist to curtail the activity
of STAT proteins. These include the action of phosphotyrosine phosphatases (PTP), suppressors of
cytokine signaling (SOCS), interaction with inhibitory proteins such as protein inhibitor of activated
STATs (PIAS), and targeted proteasome-dependent degradation of active STATs (Figure 4).
2.3.1. Phosphotyrosine Phosphatases
The PTP family is involved in the dephosphorylation of JAKs and STATs proteins. Their function
is of crucial importance to fine-tune the activities of STATs factors, but only some PTP-dependent
modulation of STAT signaling have been studied thoroughly. The best characterized of these proteins
are SHP1 and SHP2, featuring SH2 domain that recognizes the phosphotyrosine residues. Among them,
SHP1, mainly expressed in the nucleus of epithelial cells and in the cytoplasm of hematopoietic
cells, is responsible for JAKs and STATs inactivation and SHP2, ubiquitous and present both in the
cytoplasm and in the nucleus, is able to inactivate both STAT1 and STAT3. SHP2 can directly inactivate
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STAT1 dephosphorylating both p-Tyr701 and p-Ser727 residues. Indeed, the knockout of SHP2 in
mouse fibroblast cells outcomes in enhanced and prolonged STAT1 phosphorylation at both Tyr701
and Ser727 [23]. There is also evidence that SHP2 negatively regulates the activity of STAT3 since
SHP2∆/∆ mutant mouse ES cells, in the presence of leukemia inhibitory factor (LIF), showed defective
differentiation and more efficient self-renewal, partly because of an increased in STAT3 activity in the
absence of functional SHP2 [24]. Others PTP involved in the inhibition of STAT1 signaling are PTP1B,
a specific inhibitor of JAK2 and TYK2 and T-Cell PTP (TCPTP) that acts on JAK1. The nuclear isoform
of TCPTP, called TC45, not only directly dephosphorylates p-Tyr701-STAT1 inducing its export from the
nucleus but also regulates IL6-mediated signaling pathway through STAT3 dephosphorylation [25,26].
Interestingly, the tumor suppressor activity of two further PTPs has recently been linked to STAT3
inactivation: PTPRD was found frequently inactivated and unable to dephosphorylate the oncoprotein
STAT3 in glioblastoma and in other human cancers and PTPRT was shown to reduce IL-6 mediated
STAT3 activation in HCT116 cell lines [27,28].
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negative regulation. Phosphotyrosine Phosphatases (PTP) and Suppressors of Cytokine Signaling
(SOCS) dephosphorylate JAKs as well as STATs in the cytoplasm whereas the Inhibitory Proteins of
Activated ST Ts (PIAS) operate on STATs dimers in the cytoplasm as well as into the nucleus.
2.3.2. Suppressors of Cytokine Signaling
The SOCS family includes eight intracellular proteins that have a key role in protein degradation
process through the ubiquitin/proteasome pathway. SOCS proteins, such as SOCS1 and SOCS3,
are characterized by the presence of a central SH2 domain and by a conserved region, called SOCS
BOX, that directly binds the ubiquitin E3 ligase complex leading to kinases degradation [29]. The SOCS
expression is quickly induced by the sa e cytokines that trigger the JAK/STAT pathway causing the
inhibition of STATs signaling through a negative feed-back mechanism. Among the SOCS family,
SOCS1 and SOCS3 are unique in that they contain 12 amino acid region known as the kinase in ibitory
region (KIR), required for inhibition of JAK kinase activity [30,31]. SOCS1 is the most potent member of
the SOCS family and it is shown to be a direct inhibitor of the catalytic activity of JAK1, JAK2 and TYK2
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but not JAK3. Another member of the same protein family, the Cytokine-Induced SH2 domain protein
(CIS), competes with STATs for the binding to the tyrosine residues within the receptor cytoplasmic
domains [32,33].
2.3.3. Protein Inhibitor of Activated STATs
The PIAS family consists of four members (PIAS1, PIAS3, PIASX and PIASY) that interact with
STATs activated dimers preventing their association with DNA and gene transcription [34]. The specific
PIAS-STAT interaction is cytokine-dependent and, within the PIAS family, the different proteins act
through different mechanisms. PIAS1 and PIAS3 were identified as interaction partners for STAT1 and
STAT3, respectively and have been shown to function also through a SUMO E3 ligase-like mechanism
promoting the conjugation of transcriptional factors with the Small Ubiquitin-like Modifier (SUMO) [35].
Otherwise PIASY is a transcriptional corepressor of STAT1 and its LXXLL coregulator signature motif,
located at the NH2 terminus, is involved in the modulation of STAT-mediated gene expression [36].
2.4. Post-Translational Modification
Aside from the phosphorylation, STATs activity can be regulated by other post-translational
modifications such as ubiquitination, acetylation, methylation, S-glutathionylation and ISGylation.
2.4.1. Ubiquitination
Protein ubiquitination plays a role in controlling cellular signaling pathways by marking proteins,
including transcription factors, for degradation through the 26S proteosome-dependent pathway.
A STAT-interacting LIM protein (SLIM) was identified, as a STAT ubiquitin E3 ligase, for regulating the
STATs signaling pathway [37]. It has been suggested that SLIM/PDLIM2 E3 ligase targets STAT3 [38].
Yuan et al. provided evidence that Smurf1 targets STAT1 for ubiquitination and proteasomal degradation
with a negative feedback regulation on IFNγ signaling [39]. In prostate cancers STAT3 was identified
as a substrate of E3 ubiquitin ligase COP1, which is involved in its ubiquitination and degradation [40].
Otherwise, Ray et al. demonstrated that the mono-ubiquitination of Lys94 residue in the NH2-terminal
domain of STAT3 augments its transcriptional activity [41].
2.4.2. Acetylation
Histone acetyltransferase CBP prompts the acetylation of Lys410 and Lys413 residues of STAT1
leading to dissociation from the promoter sequences and induces binding of phosphatase TCP45,
which catalyzes dephosphorylation [42]. Conversely, the STAT3 acetylation of Lys49 and Lys87 located
at NH2 terminal and of Lys685 at -COOH terminal is associated with positive regulation and DNA
binding [43].
2.4.3. Methylation
Mowen et al. reported that STAT1 methylation on Arg31, mediated by Protein Methyl-Transferase
1 (PRMT1), is functionally necessary for full activation of transcription in response to IFNα/β receptor
since it suppresses the interaction with the negative regulatory protein PIAS1 [44]. Moreover, Chen et al.
identified another site of methylation on Lys525 catalyzed by the methyltransferase STD2 as an essential
signaling event for IFNα-dependent antiviral immunity. Nevertheless, STAT1 methylation needs to be
explored more thoroughly because it is at the moment controversial [45].
STAT3 is reversibly methylated on Lys residues by histone-modifying enzymes, with important
functional consequences [46]. It is known to be di- or trimethylated on Lys140 or Lys49 and Lys180
by the histone methyltransferase SET9 (SET domain containing lysine methyltransferase 9) or EZH2
(enhancer of zeste homolog 2), respectively [47]. Methylation on Lys140 blocks the binding of STAT3
to DNA, negatively affecting STAT3-dependent transcription [47]. Otherwise, Lys49 and Lys180
Int. J. Mol. Sci. 2020, 21, 7034 8 of 18
methylation enhances STAT3 tyrosine phosphorylation by protecting it from dephosphorylation,
positively affecting STAT3-dependent transcription [48].
2.4.4. S-Glutathionylation
STAT1 and STAT3 are both gluthationylated on specific cysteine residues in response to a
perturbation in the intracellular redox environment [49–51]. Intriguingly, this post translational
modification exerts opposite roles on the transduction cascade of both transcription factors. This will
be discussed in detail below.
2.4.5. ISGylation
Protein ISGylation is a ubiquitination-like post-translational modification that covalently
conjugates Interferon-Stimulated Genes (ISG) peptides to lysine residues of target proteins. ISG15 is
highly induced by type I interferons and it is involved in the positive regulation of JAK/STAT1 pathway.
It is unclear so far, whether other STAT family members involved in IFN signaling, such as STAT3,
are also subjected to ISG15 conjugation [52].
3. Redox Regulation of STAT1 and STAT3 Signaling Cascade
3.1. Oxidative Post-Translational Modifications of Proteins
Over the last two decades, oxidative post-translational modifications of proteins have emerging
as an important signaling mechanism that regulates different cellular functions in physiological as well
as pathological conditions and aging [53]. The consequences of protein oxidation depend on the type
and concentration of oxidants involved and vary from protein to protein depending on their specific
biochemical and structural characteristics [54]. Indeed, protein oxidation modifies size, hydrophobicity,
charge or polarity of specific amino acids in protein affecting its secondary and tertiary structure and
dictating the stability and activity of the whole protein.
Due to their related redox properties, cysteine residues appear to be the principal target sites for
oxidants. Specifically, at physiological pH the thiolic groups of one or more cysteines in redox-sensitive
proteins exist as reactive thiolate anions that are more nucleophilic and more susceptible to oxidation
that the non-ionized form. Different factors are involved in this process but all of them contribute to the
decrease of the pKa value associated to the thiol side chain of cysteine that usually is ∼8.25 (Figure 5).
Therefore, the reactive thiol of cysteine may function as a sensor or switch, that flips between the
reduced and oxidized state in response to altered localized redox potential [55].
Different oxidative post-translation modification of cysteine may occur in cells depending on types,
amounts and cellular localization of oxidants. Thus, reactive oxygen free radical (e.g., superoxide,
O−2; hydroxyl, ·OH; peroxides ROO) and non-radical (e.g., hydrogen peroxide) species (ROS) oxidize
the thiol of cysteine and generate sulfenic (R-SOH), sulfinic (R-SO2H) and sulfonic acid (R-SO3H)
(Figure 6).
These different oxidation states of proteins may result in diverse biological outcome causing the
fate of cells [56]. Indeed, RSOH may rapidly react with nearby thiol of the same protein or with other
thiol to form intra-or intermolecular disulfide bonds. Specifically, when RSOH react with GSH, one of
the most abundant low molecular mass thiols in cells, the result is S-glutathionylation, a reversible
post-translational modification of protein. This modification can also occur between the thyil radicals
(RS), formed by one electron oxidation of protein or GSH thiol group, and the -SH group of GSH
or protein. S-glutathionylation can be reduced back by glutaredoxins (Grx) or thioredoxins (Trx)
(Figure 7) [57–61]. These reversible processes permit redox signaling and may protect proteins from
irreversible oxidation.
On the other end, R-SO2H and R-SO3H, that result from further oxidation, may cause an irreversible
damage of proteins with permanent alteration of their function.
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The thiol groups can also be oxidized by reactive nitrogen species (RNS) to form reversible
S-nitrosothiols (R-SNO), characterized by a short half-life as a consequence of spontaneous
de-nitrosylation by excess GSH that can generate GSNO or glutathionylated protein (Figure 7).
However, few S-nitrosylated proteins become stable since S-nitrosylation induces conformational
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3.2. Redox Regulation of STAT1
Many reports suggest that STAT1 is a redox-sensitive protein, but the biological outcomes vary
according to oxidative insults and biological system examined. It has been reported that oxidative
stress caused by H2O2 treatment inhibits STAT1 phosphorylation in neuronal cells but had no effect
in non-neuronal ones [63]. On the other hand, H2O2 and/or derived ROS directly activate STAT1 in
cultured astrocytes [64], glia [65] and in vascular smooth muscle cells where STAT1 signaling promotes
cell growth [66].
Furthermore, Terui et al. describe that hypoxia and reperfusion treatment induces redox-dep ndent
STAT1 phosphoryl tion i prim ry rat hepatocytes and de o strate that STAT1 activation is involved
in cell survival [67]. Conversely, it ha been described that STAT1 activation i critic l i volv d
i ischemic cardi myocytes cells apoptosis [68]. The red x dependent activation of STAT1 is also
described in outer membranes of basilar arteries in ani al model of subarachnoid hemorrhage [69]
and in cardiomy cytes in mouse myocardial ischemia/reperfusion injury model [68]. The ability of
H2O2 to activate STAT1 cascade has been associated to an increas of JAK2 and TYK2 tyrosine kinase
activity [70–72]. Although many authors associate the ability of oxidative stress to activate
cascade to an increase of JAK2 and TYK2 tyrosin kinase activity, G ohmann et al. demonstrate
that obesity-induced oxidative stress inhibits the protein tyrosine phosphatase activity resulting in
activation of STAT1 [73]. Therefore, all ost r levant literature evide ces point out the role of tyrosine
kinase or phosphatase in redox regulation of STAT1 signaling without focusing the atte tion on STAT1
protein itself.
We recently d monstrated that H2O2 or h poxia treatment rapidly induces tyrosine
phosphorylation and cysteine glutathionylation of STAT1 in mouse microglia BV2 cells [51,74].
The a alysis of the molecular mechanism of STAT1 signaling rev aled that bot phosphorylation
and glutathionyl i contribute to activati n of STAT1 during oxid iv stress. Mass mapping
investigations indicated Cys324, in the DBD domain, and Cys492, between the DBD and LD domains
of STAT1 structure, as the main targets of S-glutathionylation in recombinant purified STAT1. It is
important to observe that the addition of the bulky negatively charged GSH moieties in the DBD
domain does not hamper JAK2 mediated STAT1 tyrosine phosphorylation and STAT1 DNA binding
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ability. A deep biochemical cellular study of the molecular mechanism of STAT1 redox regulation
confirms that Cys324 and Cys492 are the main targets of S-glutathionylation [51]. Our data propose
S-glutathionylation of STAT1 as a novel mechanism by which oxidative stress regulates STAT1 signaling
in microglia cells. This molecular mechanism has to be confirmed in another cellular model.
3.3. Redox Regulation of STAT3
STAT3 is a redox-regulated protein and its function is strictly affected by intracellular redox
environment. Although many reports confirm the influence of oxidative stress in STAT3 cascade, it is
still not clear if ROS up- or down-regulate STAT3 activation. Some authors report an increase of Tyr705
phosphorylation of STAT3 and up-regulation of its DNA-binding activity after different oxidative
stimuli [75,76]. In addition, the treatment of cells with ROS scavengers or NADPH oxidase enzyme
inhibitors, is able to prevents STAT3 activation [77]. On the other hand, many reports demonstrate that
transcriptional activity of STAT3 is impaired by oxidative stress through the oxidation of conserved
cysteine residues in STAT3 DBD domain [78,79]. Moreover, Zgheib et al. show that the activity of
STAT3 is inhibited by nitrosocyclohexyl acetate, a nitroxyl donor, through the formation of sulfenic
acid at the cysteine residues in endothelial cells [80].
Two important redox post-translational modifications in STAT3 protein, S-glutathionylation and
S-nitrosylation, have been found to inhibit its signaling pathway. They are able to hinder STAT3
phosphorylation as well as its DNA binding activity in different cell lines and in in vitro model.
The S-glutathionylation of STAT3 was firstly described in 2009 by Xie et al. The authors revealed
that this post-translational modification inhibits the phosphorylation of transcription factor and impairs
expression of its target genes in human HepG2 hepatoma cells [50]. Subsequently, our group identified
three sesquiterpene lactones able to down-modulate the activation of STAT3 through the disruption of
intracellular redox homeostasis and induction of S-glutathionylation of STAT3 [81–83]. Deepening
inside the redox regulation of STAT3 signaling, in 2014, we identified the Cys328 in the DBD domain,
and Cys542 in the LD domain as target of S-glutathionylation [49]. Although the crystal structure
of glutathionylated STAT3 is not available, it can be speculated that the addiction of GSH on STAT3
could induce a slight modification in its structure hindering accessibility to JAK2 and consequently its
phosphorylation [49–51,79].
The S-nitrosylation of STAT3 was discovered in 2015 by Kim et al. [79]. The authors demonstrated
that the addiction of NO to cysteine residues down-modulates STAT3 signaling pathway. Furthermore,
they identified Cys259 in the CCD domain of STAT3 as target of S-nitrosylation and suggested that NO
adduct perturbs domain folding impairing interaction between STAT3 and its receptor (phospho-Tyr
of gp130) and successive JAK2-mediated tyrosine phosphorylation of STAT3.
Redox regulation of STAT3 also occurs via oxidation and reduction of exposed Cys residues,
through a redox relay involving peroxiredoxin-2 (Prx2) and thioredoxin-1 (Trx1) [83,84]. Following
induction of oxidative stress by H2O2, Prx2 rapidly oxidizes STAT3 inducing the formation of
unphosphorylated STAT3 dimer transcriptionally inactive. The restore of STAT3 transcriptional activity
is due to Trx1 action that reduce oxidized STAT3 dimers and re-establishes the phosphorylation state
of STAT3 [83].
4. Concluding Remarks
This review aims to provide an overview on the oxidation mechanism of cysteine residues in the
proteins and to discuss the redox regulation of STAT1 and STAT3 signaling.
It is well known that STAT1 and STAT3 play essentially antagonistic roles and the disruption of their
balance directs cells from survival to apoptotic cell death or from inflammatory to anti-inflammatory
responses. Many authors describe a conflicting function of STAT1 and STAT3 in ischemic heart
disease where STAT1 contributes to the loss of cardiomyocytes and STAT3 protects them from I/R
injury [68,85–88]. Analogously, in neurodegenerative disorders STAT1 exerts a pro-apoptotic effect
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contributing to brain damage whereas STAT3 shows neuroprotective properties through the inhibition
of apoptosis [89,90].
Different mechanisms are proposed to explain this yin-yang relationship between STAT1 and
STAT3 signal transduction cascade. Considering the redox aspect of STATs proteins, in this review we
highlight the importance of S-glutathionylation that affects phosphorylation and dephosphorylation of
STAT1 and STAT3 exerting an opposing role in the modulation of the transduction pathway. Specifically,
modification in the intracellular redox environment induces STAT3 S-glutathionylation impairing
its phosphorylation and down-regulating its signaling. Conversely, oxidative stress induces both
phosphorylation and S-glutathionylation of STAT1 that are responsible of its aberrant activation
(Figure 8).
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and down-regulating its signaling (dashed line). Conversely, oxidative stress induces both
phosphorylation and S-glutathionylation of STAT1 that are responsible of its aberrant activation
(solid line).
Taking into account the opposing role of STAT1 and STAT3 signaling in the development of
different cardiovascular diseases as well as in neurodegenerative disorders, therapeutic strategies that
target STAT1/3 S-glutathionylation may offer new promise for drug development also in combination
with more standardized therapies.
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